Sarcoidosis 1 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

SS1 MCID: SRC025 MIFTS: 71	Sarcoidosis 1 (SS1) Categories: Bone diseases, Endocrine diseases, Eye diseases, Genetic diseases, Immune diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Sarcoidosis 1

MalaCards integrated aliases for Sarcoidosis 1:

Name: Sarcoidosis 1 ⁵⁷ ⁷³

Sarcoidosis ⁵⁷ ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ⁷³ ⁵³ ⁴¹ ⁴³ ¹⁴ ⁶³ ⁷¹ ³¹ ³³

Boeck Sarcoid ⁵⁷ ¹¹ ⁵⁸ ⁷³

Besnier-Boeck-Schaumann Disease ⁵⁸ ⁷³ ³³

Sarcoidosis, Susceptibility to, 1 ⁵⁷ ⁵

Ss1 ⁵⁷ ⁷³

Hutchinson-Boeck Disease or Syndrome ³³

Schaumann's Disease or Syndrome ³³

Lymphogranulomatosis ¹¹

Hodgkin Disease ⁷¹

Boeck's Disease ³³

Boeck's Sarcoid ³³

Characteristics:

Inheritance:

Sarcoidosis 1: Autosomal dominant ⁵⁷

Sarcoidosis: Multigenic/multifactorial ⁵⁸

Prevelance:

Sarcoidosis: 6-9/10000 (United States, Switzerland, Czech Republic) 1-5/10000 (Worldwide, Ireland, Europe, France, Finland, Italy, Sweden, Norway, Norway, Canada, Guadeloupe) 1-9/100000 (Croatia, United Kingdom, Spain, Denmark, Switzerland, Greece, Greece, Iceland, Czech Republic, Australia, Japan, Japan, France, Taiwan, Province of China, Guadeloupe) 1-9/1000000 (Korea, Republic of, Singapore, Portugal, Uruguay) >1/1000 (Sweden) ⁵⁸

Age Of Onset:

Sarcoidosis: Adolescent,Adult,Childhood,Elderly ⁵⁸

OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Miscellaneous:
generalized fatigue
onset usually before age 40 years
systemic granulomatous disease
u.s. frequency higher in blacks than whites

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Immune diseases Neuronal diseases Eye diseases Nephrological diseases Respiratory diseases Bone diseases Endocrine diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

Certain disorders involving the immune mechanism

Sarcoidosis

Sarcoidosis of lung

Sarcoidosis of lung with sarcoidosis of lymph nodes

Sarcoidosis of lymph nodes

Sarcoidosis of other and combined sites

Sarcoidosis of skin

Sarcoidosis, unspecified

ICD11: ³³

Diseases of the immune system

Certain disorders involving the immune system

Sarcoidosis

Other specified sarcoidosis

Sarcoidosis, unspecified

Orphanet: ⁵⁸

Rare neurological diseases

Rare eye diseases

Rare renal diseases

Rare respiratory diseases

Rare systemic and rhumatological diseases

Rare endocrine diseases

External Ids:

Disease Ontology ¹¹ DOID:11335

OMIM® ⁵⁷ 181000

ICD9CM ³⁴ 135

MeSH ⁴³ D012507

NCIt ⁴⁹ C34995

SNOMED-CT ⁶⁸ 154425004

ICD10 ³¹ D86 D86.9

MESH via Orphanet ⁴⁴ D012507

ICD10 via Orphanet ³² D86.0 D86.1 D86.2 more

UMLS via Orphanet ⁷² C0036202

Orphanet ⁵⁸ ORPHA797

MedGen ⁴⁰ C2697310 CN034668

SNOMED-CT via HPO ⁶⁹ 10890000 111516008 112643007 more

ICD11 ³³ 330792642 330792642/other 330792642/unspecified

UMLS ⁷¹ C0019829 C0036202

Sources

Summaries for Sarcoidosis 1

MedlinePlus: ⁴¹ Sarcoidosis is a disease that leads to inflammation, usually in your lungs, skin, or lymph nodes. It starts as tiny, grain-like lumps, called granulomas. Sarcoidosis can affect any organ in your body. No one is sure what causes sarcoidosis. It affects men and women of all ages and races. It occurs mostly in people ages 20 to 50, African Americans, especially women, and people of Northern European origin. Many people have no symptoms. If you have symptoms, they may include: Cough Shortness of breath Weight loss Night sweats Fatigue Tests to diagnose sarcoidosis include chest x-rays, lung function tests, and a biopsy. Not everyone who has the disease needs treatment. If you do, prednisone, a type of steroid, is the main treatment. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary: Sarcoidosis 1, also known as sarcoidosis, is related to blau syndrome and cardiac sarcoidosis, and has symptoms including snoring and coughing. An important gene associated with Sarcoidosis 1 is HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Azathioprine and Pirfenidone have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and eye, and related phenotypes are fatigue and fever

PubMed Health : ⁶³ Sarcoidosis: Sarcoidosis (sar-koy-DO-sis) is a disease of unknown cause that leads to inflammation. This disease affects your body’s organs. Normally, your immune system defends your body against foreign or harmful substances. For example, it sends special cells to protect organs that are in danger. These cells release chemicals that recruit other cells to isolate and destroy the harmful substance. Inflammation occurs during this process. Once the harmful substance is gone, the cells and the inflammation go away. In people who have sarcoidosis, the inflammation doesn't go away. Instead, some of the immune system cells cluster to form lumps called granulomas (gran-yu-LO-mas) in various organs in your body.

Orphanet: ⁵⁸ A rare multisystemic, autoinflammatory disorder of unknown etiology characterized by the formation of immune, non-caseating granulomas in any organ(s), leading to variable clinical symptoms and severity. Clinical presentation is typically with persistent dry cough, eye or skin manifestations, peripheral lymph nodes, fatigue, weight loss, fever or night sweats, and Löfgren syndrome.

UniProtKB/Swiss-Prot: ⁷³ An idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved.

Disease Ontology: ¹¹ A hypersensitivity reaction type IV disease characterized by the growth of collections of inflammatory cells (granulomas) in multiple organs.

Wikipedia: ⁷⁵ Sarcoidosis (also known as Besnier-Boeck-Schaumann disease) is a disease involving abnormal collections... more...

More information from OMIM: 181000

Sources

Related Diseases for Sarcoidosis 1

Diseases in the Sarcoidosis 1 family:

Sarcoidosis 2

Sarcoidosis 3

Diseases related to Sarcoidosis 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1899)

#	Related Disease	Score	Top Affiliating Genes
1	blau syndrome	33.2	TNF NOD2 IL1B
2	cardiac sarcoidosis	33.2	TNF BTNL2 ACE
3	skin sarcoidosis	33.1	TNF IFNG CCR6 ACE
4	melkersson-rosenthal syndrome	32.6	TNF NOD2 ACE
5	pars planitis	32.5	HLA-DRB1 CCR6 ACE
6	interstitial lung disease	32.3	TNF SERPINA3 IL1B IL18 IFNG CCR6
7	retinal vasculitis	32.3	TNF CCR6 CCL2 ACE
8	uveoparotid fever	32.2	HLA-DRB1 ACE
9	intermediate uveitis	32.2	TNF IL2RA IFNG CXCR3 CCR6 ACE
10	uveitis	32.1	TNF NOD2 IL2RA IL1B IFNG HLA-DRB1
11	erythema nodosum	31.9	TNF NOD2 IL1B IFNG
12	extrinsic allergic alveolitis	31.9	TNF IL2RA IL18 CXCR3 CCR6 CCL3
13	pulmonary fibrosis	31.9	IL1B CXCR3 CCL3 CCL2 CCL18
14	lung disease	31.8	TNF SERPINA3 SCGB1A1 IL1B IFNG CXCR3
15	vasculitis	31.7	TNF SERPINA3 IL1B HLA-DRB1 CCL2
16	anterior uveitis	31.7	TNF SERPINA3 IL1B IFNG HLA-DRB1 CCR6
17	interstitial nephritis	31.6	TNF CCR6 ACE
18	choroiditis	31.5	TNF IFNG CCR6 ACE
19	posterior uveitis	31.5	TNF IL2RA CCR6 ACE
20	myocarditis	31.5	TNF IL1B IL18 IL12RB1 IFNG CXCL9
21	interstitial lung disease 2	31.5	TNF SERPINA3 SCGB1A1 IL1B IL18 IFNG
22	spondyloarthropathy 1	31.4	TNF NOD2 IL1B CCR6
23	berylliosis	31.4	IFNG HLA-DRB1 ACE
24	exanthem	31.4	TNF IL1B IL18 IFNG CCR6 ACE
25	primary biliary cholangitis	31.4	TNF IL1B IL12RB1 HLA-DRB1 CCR6 CCL2
26	chronic granulomatous disease	31.4	TNF IL1B IL12RB1 IFNG
27	glomerulonephritis	31.4	TNF SCGB1A1 IL1B CXCL9 CCL2 ACE
28	pulmonary tuberculosis	31.4	TNF IL2RA IL1B IL18 IL12RB1 IFNG
29	panuveitis	31.4	TNF SERPINA3 NOD2 IL1B IFNG HLA-DRB1
30	alopecia	31.4	TNF IL1B IFNG HLA-DRB1
31	autoimmune disease	31.4	TNF IL2RA IL1B IL18 IFNG HLA-DRB1
32	systemic scleroderma	31.4	TNF IL1B HLA-DRB1 CCR6 CCL2 CCL18
33	crohn's disease	31.4	TNF SERPINA3 NOD2 IL1B IL18 IFNG
34	chronic beryllium disease	31.4	IL18 IFNG HLA-DRB1
35	myositis	31.4	TNF SERPINA3 IL1B IFNG HLA-DRB1
36	respiratory failure	31.4	TNF SERPINA3 SCGB1A1 IL1B IL18 IFNG
37	inflammatory bowel disease 1	31.4	TNF NOD2 IL1B CCR6
38	macular retinal edema	31.4	TNF IL1B CCL2 ACE
39	allergic disease	31.3	TNF SERPINA3 IL1B IFNG CCR6 CCL3
40	leprosy 3	31.3	TNF SERPINA3 NOD2 IL1B IL18 IFNG
41	thyroiditis	31.3	TNF IL1B IFNG HLA-DRB1
42	bronchiectasis	31.3	TNF SERPINA3 IL1B IFNG
43	aspergillosis	31.3	TNF NOD2 IL1B IL18 IFNG HLA-DRB1
44	kidney disease	31.3	TNF IL1B IL18 IFNG CCL2 ACE
45	portal hypertension	31.3	TNF CCR6 ACE
46	pneumoconiosis	31.3	TNF IL1B HLA-DRB1 CCL2
47	histoplasmosis	31.3	TNF IL12RB1 IFNG HLA-DRB1 CCR6
48	cryptococcosis	31.3	TNF IFNG CCR6
49	optic nerve disease	31.2	TNF SERPINA3 IL1B HLA-DRB1 CCR6 ACE
50	spondylitis	31.2	TNF NOD2 IL1B IFNG HLA-DRB1 CCR6

Graphical network of the top 20 diseases related to Sarcoidosis 1:

Sources

Symptoms & Phenotypes for Sarcoidosis 1

Human phenotypes related to Sarcoidosis 1:

⁵⁸ ³⁰ (show top 50) (show all 101)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	fatigue ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012378
2	fever ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001945
3	thrombocytopenia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001873
4	dyspnea ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002094
5	joint swelling ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001386
6	uveitis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000554
7	cough ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012735
8	chest pain ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0100749
9	weight loss ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001824
10	leukopenia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001882
11	erythema nodosum ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012219
12	increased t cell count ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0100828
13	facial palsy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0010628
14	cataract ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000518
15	hepatomegaly ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002240
16	blindness ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000618
17	renal insufficiency ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000083
18	portal hypertension ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001409
19	alopecia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001596
20	bronchiectasis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002110
21	nephrolithiasis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000787
22	pneumothorax ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002107
23	diabetes insipidus ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000873
24	subcutaneous nodule ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001482
25	emphysema ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002097
26	glaucoma ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000501
27	nephrocalcinosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000121
28	hypercalciuria ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002150
29	hypercalcemia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003072
30	peripheral neuropathy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0009830
31	hepatic failure ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001399
32	abnormality of the gastrointestinal tract ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0011024
33	bone cyst ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012062
34	keratoconjunctivitis sicca ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001097
35	hypopigmentation of the skin ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001010
36	heart block ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012722
37	lymphadenopathy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002716
38	upper airway obstruction ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002781
39	pulmonary fibrosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002206
40	proximal muscle weakness ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003701
41	tubulointerstitial nephritis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001970
42	dacryocystitis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000620
43	scarring ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0100699
44	skin plaque ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0200035
45	chylothorax ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0010310
46	ventricular tachycardia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0004756
47	hyperpigmentation of the skin ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000953
48	maculopapular exanthema ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0040186
49	abnormal reproductive system morphology ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012243
50	abnormal liver parenchyma morphology ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0030146

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Head And Neck Eyes:
photophobia
glaucoma
uveitis
iridocyclitis
blurred vision
more

Abdomen Gastrointestinal:
anorexia
associated inflammatory bowel disease

Laboratory Abnormalities:
hypercalciuria
elevated erythrocyte sedimentation rate (esr)
elevated serum angiotensin-converting enzyme (ace)
positive kveim-siltzbach skin test
mononuclear cell noncaseating granulomatous inflammation on biopsy (lung, skin, lip)

Immunology:
generalized lymphadenopathy
hyperglobulinemia
activated t-helper cells
activated mononuclear phagocytes
exaggerated cellular immune processes

Head And Neck Mouth:
enlarged salivary glands

Abdomen Liver:
hepatomegaly may occur
elevated liver function tests may occur

Neurologic Central Nervous System:
neurosarcoidosis (5-16% of patients)

Metabolic Features:
fever

Respiratory:
dyspnea
cough

Growth Weight:
weight loss

Skeletal:
polyarthritis
bone cysts

Respiratory Lung:
bilateral hilar adenopathy
pulmonary parenchymal infiltration
pulmonary function tests show interstitial lung disease

Abdomen Spleen:
splenomegaly may occur

Hematology:
bone marrow involvement may cause pancytopenia

Clinical features from OMIM®:

181000 (Updated 08-Dec-2022)

UMLS symptoms related to Sarcoidosis 1:

snoring; coughing

MGI Mouse Phenotypes related to Sarcoidosis 1:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.19	ACE BTNL2 CCL18 CCL2 CCL3 CCR6
2	neoplasm	MP:0002006	9.92	ACE BTNL2 CCL2 CXCR3 IFNG IL1B
3	immune system	MP:0005387	9.91	ACE BTNL2 CCL18 CCL2 CCL3 CCR6
4	digestive/alimentary	MP:0005381	9.81	BTNL2 CCL18 CCL2 CCL3 IFNG IL18
5	hematopoietic system	MP:0005397	9.55	ACE BTNL2 CCL18 CCL2 CCL3 CCR6

Sources

Drugs & Therapeutics for Sarcoidosis 1

PubMed Health treatment related to Sarcoidosis 1: ⁶³

Not everyone who has sarcoidosis needs treatment . Sometimes the disease goes away on its own. Whether you need treatment and what type of treatment you need depend on your signs and symptoms, which organs are affected, and whether those organs are working well. If the disease affects certain organs —such as your eyes , heart , or brain —you'll need treatment even if you don't have any symptoms. In either case, whether you have symptoms or not, you should see your doctor for ongoing care. He or she will want to check to make sure that the disease isn't damaging your organs . For example, you may need routine lung function tests to make sure that your lungs are working well. If the disease isn't worsening, your doctor may watch you closely to see whether the disease goes away on its own. If the disease does start to get worse, your doctor can prescribe treatment . The goals of treatment include: Relieving symptoms Improving organ function Controlling inflammation and reducing the size of granulomas (inflamed lumps) Preventing pulmonary fibrosis (lung scarring ) if your lungs are affected Your doctor may prescribe topical treatments and/or medicines to treat the disease.

Drugs for Sarcoidosis 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 484)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Azathioprine

Approved

Phase 4

446-86-6

2265

Pirfenidone

Approved, Investigational

Phase 4

53179-13-8

40632

Riociguat

Approved

Phase 4

625115-55-1

11304743

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Methylphenidate

Approved, Investigational

Phase 4

113-45-1

4158

Iloprost

Approved, Investigational

Phase 4

78919-13-8

6443959 6435378 5311181

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Pentoxifylline

Approved, Investigational

Phase 4

6493-05-6

4740

Cisplatin

Approved

Phase 4

15663-27-1

2767 5702198 441203

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

Levoleucovorin

Approved, Experimental, Investigational

Phase 4

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Prednisolone phosphate

Approved, Vet_approved

Phase 4

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 4

52-21-1

Prednisolone

Approved, Vet_approved

Phase 4

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 4

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 4

83-43-2

4159 6741

Methotrexate

Approved

Phase 4

1959-05-2, 59-05-2

4112 126941

Triamcinolone

Approved, Vet_approved

Phase 4

124-94-7

31307

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 4

67-97-0, 1406-16-2

5280795 10883523

Ergocalciferol

Approved, Nutraceutical

Phase 4

50-14-6

5280793

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

Prednisolone hemisuccinate

Experimental

Phase 4

2920-86-7

4897

Central Nervous System Stimulants

Phase 4

Dopamine Uptake Inhibitors

Phase 4

Dopamine Agents

Phase 4

Dexmethylphenidate Hydrochloride

Phase 4

Anesthetics, Intravenous

Phase 4

Anesthetics, General

Phase 4

Protective Agents

Phase 4

Radiation-Protective Agents

Phase 4

Phosphodiesterase Inhibitors

Phase 4

Vasodilator Agents

Phase 4

Platelet Aggregation Inhibitors

Phase 4

Antioxidants

Phase 4

Vitamin D2

Phase 4

3249

Calciferol

Phase 4

Ergocalciferols

Phase 4

Citrate

Phase 4

Folic Acid Antagonists

Phase 4

Folate

Phase 4

Vitamin B9

Phase 4

Vitamin B Complex

Phase 4

Methylprednisolone Acetate

Phase 4

584547

Triamcinolone hexacetonide

Phase 4

Triamcinolone diacetate

Phase 4

Triamcinolone Acetonide

Phase 4

6436

Apremilast

Approved, Investigational

Phase 2, Phase 3

608141-41-9

10151715 11561674

Sirolimus

Approved, Investigational

Phase 3

53123-88-9

5284616 6436030

Bosentan

Approved, Investigational

Phase 2, Phase 3

147536-97-8

104865

Interventional clinical trials:

(show top 50) (show all 1013)

#	Name	Status	NCT ID	Phase	Drugs
1	ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS)	Unknown status	NCT02188017	Phase 4	Acthar gel
2	Pirfenidone for Progressive Fibrotic Sarcoidosis	Unknown status	NCT03260556	Phase 4	Pirfenidone;Placebos
3	A Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary Hypertension	Unknown status	NCT02625558	Phase 4	Riociguat;Placebo
4	Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)	Unknown status	NCT01830959	Phase 4	Roflumilast;Placebo
5	Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy	Unknown status	NCT00188149	Phase 4	Combined chemotherapy (ABVD, BACOPP-D)
6	Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma	Unknown status	NCT02526823	Phase 4	R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
7	A Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary Sarcoidosis	Completed	NCT03320070	Phase 4	Acthar Gel;Placebo
8	Inhaled Iloprost for Sarcoidosis Associated Pulmonary Hypertension	Completed	NCT00403650	Phase 4	Iloprost
9	Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel	Completed	NCT02298491	Phase 4	H.P. Acthar Gel
10	d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis	Completed	NCT03549598	Phase 4	68Ga-DOTATATE PET/CT;18FDG PET/CT scan;13NH3 PET/CT scan
11	Randomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in the Treatment of Fatigue in Sarcoidosis Subjects.	Completed	NCT00361387	Phase 4	d-methylphenidate
12	Target-controlled Versus Manually-controlled Propofol Sedation in Flexible Bronchoscopy. A Randomized Non-inferiority Trial.	Completed	NCT02246023	Phase 4
13	Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial.	Completed	NCT01658280	Phase 4
14	A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy	Completed	NCT01990534	Phase 4	Brentuximab Vedotin
15	The PREDMETH Trial: Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis - A Randomized Controlled Trial	Recruiting	NCT04314193	Phase 4	Methotrexate;Prednisolone
16	Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis: a Randomized Controlled Trial	Recruiting	NCT03265405	Phase 4	Low dose prednisolone;Medium dose prednisolone
17	A Prospective Multi-center Study for the Treatment of Chinese Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma Using a Modified COG Strategy	Recruiting	NCT04726501	Phase 4
18	Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy.	Recruiting	NCT03500133	Phase 4	Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
19	Enhancing Effect on Tumour Apoptosis With the Combined Use of Pentoxifylline Plus Chemotherapeutical Agents in Pediatrics and AYA Patients With Hodgkin´s Lymphoma	Recruiting	NCT05490953	Phase 4	Pentoxifylline;Placebo
20	Vitamin D Homeostasis in Sarcoidosis	Active, not recruiting	NCT03621553	Phase 4	Ergocalciferol;Placebo;Calcium Citrate with Vitamin D2
21	First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents	Active, not recruiting	NCT01088750	Phase 4	cyclophosphamide;prednisolone;vinblastine sulfate
22	Use of CXCL9 as a Biomarker of Acthar Efficacy	Not yet recruiting	NCT02523092	Phase 4	Acthar gel
23	Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD")	Terminated	NCT00747461	Phase 4
24	Corticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATE	Terminated	NCT00918554	Phase 4	Methotrexate;Placebo
25	CArdiac Sarcoidosis Response TO steRoids (CASTOR) Trial	Withdrawn	NCT01210677	Phase 4	Prednisone
26	ACTHAR Therapy for Central Nervous System Sarcoidosis	Withdrawn	NCT02920710	Phase 4	Repository Corticotropin Injection
27	ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial	Unknown status	NCT02348905	Phase 2, Phase 3	ACTHAR Gel 40 units twice weekly;ACTHAR Gel 80 units twice weekly.
28	ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study	Unknown status	NCT02155803	Phase 2, Phase 3	ACTHAR Gel (adrenocorticotropic hormone)
29	Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis	Unknown status	NCT02824419	Phase 2, Phase 3	Methionine;DOTANOC
30	Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis	Unknown status	NCT01920919	Phase 3	Dexamethasone;Placebo
31	Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma	Unknown status	NCT00816959	Phase 3	R-mabHDI and ABVD;ABVD
32	Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.	Unknown status	NCT02722733	Phase 3	G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
33	HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET	Unknown status	NCT00736320	Phase 3	ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)
34	Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy	Unknown status	NCT00002987	Phase 3	cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
35	A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease)	Unknown status	NCT00003924	Phase 3
36	The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis	Completed	NCT00794274	Phase 2, Phase 3	CC-100004
37	Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial.	Completed	NCT02200146	Phase 3	Prednisone;Hydroxychloroquine + Prednisone
38	Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES STUDY)	Completed	NCT03704610	Phase 3	Infliximab;Placebo
39	Use of Armodafinil (R-modafinil) for Fatigue in Sarcoidosis	Completed	NCT00555347	Phase 2, Phase 3	Armodafinil;Placebo
40	Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension	Completed	NCT00851929	Phase 2, Phase 3	Ambrisentan
41	Determination of the Efficacy and Safety of the Seasonal Influenza Vaccine Among Patients Suffering From Sarcoidosis.	Completed	NCT01687517	Phase 3	Seasonal influenza vaccine available for the 2012-2013 vaccine campaign
42	Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension	Completed	NCT00581607	Phase 2, Phase 3	Bosentan;Placebo
43	A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (Remicade�) in Subjects With Chronic Sarcoidosis With Pulmonary Involvement.	Completed	NCT00073437	Phase 3	Infliximab
44	Endosonography (EUS and EBUS) vs Conventional Bronchoscopy for the Diagnosis of Sarcoidosis: a Randomized Trial	Completed	NCT00872612	Phase 3
45	Randomized Controlled Trial of Thalidomide vs Placebo in Skin Sarcoidosis	Completed	NCT00305552	Phase 3	THALIDOMIDE
46	Tadalafil for Sarcoidosis Associated Pulmonary Hypertension	Completed	NCT01324999	Phase 2, Phase 3	Tadalafil
47	A Study Evaluating the Effect of the Number of Needle Revolutions Inside the Node on the Diagnostic Yield of EBUS-TBNA in Sarcoidosis	Completed	NCT02875756	Phase 2, Phase 3
48	"A RCT ON CLINICAL EFFICACY OF 1% vs. 2% LIGNOCAINE IN COUGH SUPPRESSION AND PAIN RELIEF IN PATIENTS UNDERGOING FLEXIBLE BRONCHOSCOPY"	Completed	NCT01955824	Phase 2, Phase 3	1% lignocaine;2% lignocaine
49	A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease	Completed	NCT00025259	Phase 3	Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
50	A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease	Completed	NCT00302003	Phase 3	doxorubicin hydrochloride;vincristine sulfate;prednisone;cyclophosphamide;ifosfamide;vinorelbine tartrate;dexamethasone;etoposide phosphate;cisplatin;cytarabine

Search NIH Clinical Center for Sarcoidosis 1

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Carmustine

Chlorambucil

Cisplatin

CISPLATIN PWDR

Cyclophosphamide

Dacarbazine

Ifosfamide

Lomustine

Mechlorethamine

Mechlorethamine hydrochloride

pembrolizumab

Procarbazine

Procarbazine Hydrochloride

sargramostim

Vinblastine

Vinblastine Sulfate

Vincristine

Vincristine Sulfate

vinorelbine

Vinorelbine tartrate

Cochrane evidence based reviews: sarcoidosis

Sources

Genetic Tests for Sarcoidosis 1

Sources

Anatomical Context for Sarcoidosis 1

Organs/tissues related to Sarcoidosis 1:

MalaCards : Lung, Skin, Eye, Liver, Heart, Bone, T Cells

Sources

Publications for Sarcoidosis 1

Articles related to Sarcoidosis 1:

(show top 50) (show all 28890)

#	Title	Authors	PMID	Year
1	HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. ⁶² ⁵⁷ ⁵	Rossman MD...ACCESS Group	14508706	2003
2	Association between SLC11A1 (formerly NRAMP1) and the risk of sarcoidosis in Poland. ⁵³ ⁶² ⁵⁷	Dubaniewicz A...Blackwell JM	15702130	2005
3	Association between IFNA genotype and the risk of sarcoidosis. ⁵³ ⁶² ⁵⁷	Akahoshi M...Shirakawa T	15004750	2004
4	Association between heat shock protein 70/Hom genetic polymorphisms and uveitis in patients with sarcoidosis. ⁶² ⁵⁷	Spagnolo P...Welsh KI	17591867	2007
5	Demographic-related variations in posterior segment ocular sarcoidosis. ⁶² ⁵⁷	Khalatbari D...Jaffe GJ	15019390	2004
6	Results from a genome-wide search for predisposing genes in sarcoidosis. ⁶² ⁵⁷	Schurmann M...Schwinger E	11549543	2001
7	Design of a case control etiologic study of sarcoidosis (ACCESS). ACCESS Research Group. ⁶² ⁵⁷		10580780	1999
8	[Familial sarcoidosis. 4 cases from 2 families]. ⁶² ⁵⁷	Kronauer CM...Russi EW	3070740	1988
9	Genetic aspects of sarcoidosis. Class II histocompatibility antigens and a family study. ⁶² ⁵⁷	Nowack D...Goebel KM	3827423	1987
10	Familial occurrence of sarcoidosis and Crohn's disease. ⁶² ⁵⁷	Gronhagen-Riska C...Koskimies S	6134089	1983
11	Familial sarcoidosis with multiple occurrences in eleven families: a possible mechanism of inheritance. ⁶² ⁵⁷	Headings VE...hackney RL	1067023	1976
12	Familial sarcoidosis: a possible genetic influence. ⁶² ⁵⁷	Sharma OP...James DG	1067024	1976
13	Familial sarcoidosis. Report of four siblings with acute sarcoidosis. ⁶² ⁵⁷	Sharma OP...Balchum OJ	5558993	1971
14	Sarcoidosis and Crohn disease in siblings. ⁶² ⁵⁷	Willoughby JM...Wilson JD	5558992	1971
15	SARCOIDOSIS. I. FAMILIAL OCCURRENCE. II. PSEUDOTUMOR CEREBRI AND UNUSUAL SKIN LESIONS. ⁶² ⁵⁷	ALLISON JR	14104643	1964
16	Epidemiologic investigations of sarcoidosis. III. Serum proteins; syphilis; association with tuberculosis: familial aggregation. ⁶² ⁵⁷	BUCK AA...McKUSICK VA	13874291	1961
17	Value of CT spectral imaging in the differential diagnosis of sarcoidosis and Hodgkin's lymphoma based on mediastinal enlarged lymph node: A STARD compliant article. ⁶² ⁴¹	Cao L...Liu Y	36451380	2022
18	Performance of Serum Angiotensin-Converting Enzyme in Diagnosing Sarcoidosis and Predicting the Active Status of Sarcoidosis: A Meta-Analysis. ⁶² ⁴¹	Hu X...Chen L	36291609	2022
19	Altered transcription factor targeting is associated with differential peripheral blood mononuclear cell proportions in sarcoidosis. ⁶² ⁴¹	Ascoli C...Finn PW	36311769	2022
20	NOD2-associated diseases: Bridging innate immunity and autoinflammation. ⁵³ ⁶²	Borzutzky A...Dedeoglu F	19467619	2010
21	Sarcoidosis following Cushing's syndrome: A report of two cases and review of the literature. ⁵³ ⁶²	Schaefer S...Kann PH	20162506	2010
22	The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. ⁵³ ⁶²	Wijnen PA...Drent M	20070603	2010
23	Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. ⁵³ ⁶²	Massara A...Trotta F	19147181	2010
24	Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. ⁵³ ⁶²	Chen ES...Moller DR	19910611	2010
25	CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis. ⁵³ ⁶²	Sato H...Welsh KI	19679608	2010
26	Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. ⁵³ ⁶²	Boot RG...Aerts JM	19808030	2010
27	Elevation of surfactant protein D, a pulmonary disease biomarker, in the sera of uveitis patients with sarcoidosis. ⁵³ ⁶²	Kitaichi N...Ohno S	20151281	2010
28	A case of early-onset sarcoidosis with a six-base deletion in the NOD2 gene. ⁵³ ⁶²	Sakai H...Nakahata T	19854854	2010
29	Targeting the TNF-alpha pathway in sarcoidosis. ⁵³ ⁶²	Antoniu SA	20001207	2010
30	Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFalpha blockade. Efficacy of rituximab, report of a single case. ⁵³ ⁶²	Dasilva V...Euller-Ziegler L	20022779	2010
31	Lack of association of immune-response-gene polymorphisms with susceptibility to sarcoidosis in Slovenian patients. ⁵³ ⁶²	Maver A...Peterlin B	20082271	2010
32	Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge. ⁵³ ⁶²	van der Stoep D...Wouters J	19966199	2009
33	Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. ⁵³ ⁶²	Bolat S...Trebst C	19755199	2009
34	Angiotensin I-converting enzyme mutation (Trp1197Stop) causes a dramatic increase in blood ACE. ⁵³ ⁶²	Nesterovitch AB...Danilov SM	20011602	2009
35	[Radiographic healing of sarcoid bone erosion]. ⁵³ ⁶²	Blank N...Lorenz HM	19756665	2009
36	Antimycobacterial immune responses in patients with pulmonary sarcoidosis. ⁵³ ⁶²	Horster R...Lange C	20298409	2009
37	CXCR3 ligands are augmented during the pathogenesis of pulmonary sarcoidosis. ⁵³ ⁶²	Busuttil A...Belperio JA	19386686	2009
38	Variation in the lymphotoxin-alpha/tumor necrosis factor locus modifies risk of erythema nodosum in sarcoidosis. ⁵³ ⁶²	McDougal KE...ACCESS Research Group	19225544	2009
39	Hypothesis: sarcoidosis is a STAT1-mediated disease. ⁵³ ⁶²	Rosenbaum JT...Planck SR	19464956	2009
40	Chemokine receptors in a regulation of interstitial lung fibrosis and inflammation. ⁵³ ⁶²	Sterclova M...Striz I	19842835	2009
41	18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. ⁵³ ⁶²	Keijsers RG...Grutters JC	19259660	2009
42	Cardiac infiltration in early-onset sarcoidosis associated with a novel heterozygous mutation, G481D, in CARD15. ⁵³ ⁶²	Okada S...Kobayashi M	19359344	2009
43	International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). ⁵³ ⁶²	Herbort CP...members of Scientific Committee of First International Workshop on Ocular Sarcoidosis	19585358	2009
44	Cytokine gene polymorphisms and BALF cytokine levels in interstitial lung diseases. ⁵³ ⁶²	Vasakova M...Striz I	19117745	2009
45	Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. ⁵³ ⁶²	Vasakova M...Striz I	19281539	2009
46	Atypical sarcoidosis: case reports and review of the literature. ⁵³ ⁶²	Giovinale M...Manna R	19530510	2009
47	Protein levels of CC chemokine ligand (CCL)15, CCL16 and macrophage stimulating protein in patients with sarcoidosis. ⁵³ ⁶²	Arakelyan A...Petrek M	19220835	2009
48	Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease. ⁵³ ⁶²	Fortunati E...Van den Bosch vJ	19077082	2009
49	Disseminated cryptococcal infection and anti-tumor necrosis factor-alpha treatment for refractory sarcoidosis: an expected association? ⁵³ ⁶²	Arnaud L...Piette JC	19208587	2009
50	Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. ⁵³ ⁶²	Thielen AM...Laffitte E	19468200	2009

Sources

Genes for Sarcoidosis 1

Genes related to Sarcoidosis 1 (3 elite genes):

(show top 50) (show all 73)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	Protein Coding	616.88	Molecular basis known ⁵⁷ Susceptibility factor ⁵⁷ ⁵⁸ Risk factor ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders (show sections)	14508706 22991420 15713215 (more) 7742275 12554629
2	SS3	Sarcoidosis, Susceptibility To, 3	Genetic Locus	50	MalaCards inferred ³⁹
3	BTNL2	Butyrophilin Like 2	Protein Coding	41.53	Susceptibility factor ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15735647 17661910 17927685 (more) 17610417
4	ACE	Angiotensin I Converting Enzyme	Protein Coding	18.56	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9098308 11475558 1344045 (more) 8564143 15781381 8256006 9817709 19259660 17123620 16901684 16133026 1664954 8213873 1316603 9657660 8795663 10672133 15025429 9726736 1668804 12677943 9373478 9327039 17768594 10192763 17492847 1668848 2176061 11168787 2164201 8154388 9713444 9307053 11481579 8594636 18496980 2175927 8164397 11334315 8721898 8046841 1668875 10868493 9230757 2154343 17043488 16505042 14556078 7734665 10207944 9813973 19218675 18049432 12677950 15948122 1663362 10993497 8887934 7809492 1405089 2067152 1648119 20011602 19756665 19530510 9649812 11505631 11463587 9611924 1372784 1942998 2162436 2157267 19585358 19070256 8318353 1942648 19755199 12861672 12653850 12005216 19035225 18051786 11403752 9987484 10386131 9513645 9274601 9088025 8950081 8046840 8256039 2355691 17929471 11983201 11485583 10362030 15281434 11251374
5	TNF	Tumor Necrosis Factor	Protein Coding	15.2	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10335007 1695561 10547277 (more) 15653992 17261090 20001207 11812354 18062795 2162537 12661995 7663784 11434729 2299255 8893383 20298289 8834333 8219777 12405487 1344039 16837501 8473683 10488747 9344512 11200748 11243953 18451575 12921647 9927365 18475478 8027394 19225544 19337437 17560312 14555589 11411907 8179912 8449077 19147181 11326956 16247590 19382527 12449172 11354543 11091281 8505857 10947879 15332393 14977779 19468200 9372680 1849808 15713215 8793473 7474565 11956055 9087946 8046825 18173203 15663335 12582407 14962969 17768594 14614765 16881227 19023492 18330749 8432140 15626311 2252243 11243939 9353154 8984099 1731582 20070603 19910611 19966199 20022779 16208666 17520259 16840744 14975942 14674007 12463467 11792075 10573228 8435295 12884466 19208587 19117745 18162998 17985412 12746045 12659618 12475802 9300729 8762499 7615305 7905208 17420690
6	NOD2	Nucleotide Binding Oligomerization Domain Containing 2	Protein Coding	14.85	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18384487 16397396 18773284 (more) 20298285 14621080 14597055 19679608 17968944 16935475 17372104 17009307 16303101 17916199 17393391 15459013 19854854 17690884 19116920 19359344 19467619 17207093
7	CHIT1	Chitinase 1	Protein Coding	13.94	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17347558 18487875 19347743 (more) 17631992 18609101 18069420 19808030 15025429 17534622 17252260
8	IFNG	Interferon Gamma	Protein Coding	13.5	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11123348 17937104 18051824 (more) 15554077 1572093 18654018 10957763 11069843 10207939 15019280 1555475 2106525 1284854 9311498 11091281 9834133 8834333 7774049 18976443 14734606 14977779 12746045 1849808 15881275 11028653 9500293 8386185 1555841 11208635 9353154 8032714 19117745 16432996 15004750 10444517 10573228 1344039 1907694 20298409 12885947 12366781 12233067 10453892 10398109 9764948 8893383 16100009 15230818 18226232 9032124 8648147 7844919 7921434 2119953 16505042 11961430 11817671 15115868 9300729 7474942 8016795 18783477 12930372 12670722 11909970 9097918 2107589 17980570 17684290 8140305 1806183 15281432
9	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	12.41	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1327664 2171882 1678021 (more) 9686498 7809492 10418818 10950894 8752945 8519382 15281434 1907694 8164397 7570437 8031681 12928233 12708075 18030581 7680189 9762805 1358556 19259660 1753540 7907809 20162506
10	IL18	Interleukin 18	Protein Coding	11.94	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11123348 12735669 11035116 (more) 17015003 12006423 16837501 11580222 16053025 16420594 12366781 11069843 16100009 15554077 15140035 10543274 15230818 11580219 17671745 19910611 19218675
11	CXCR3	C-X-C Motif Chemokine Receptor 3	Protein Coding	11.39	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9834133 17052298 19386686 (more) 19842835 16100013 15956791 14977779
12	SCGB1A1	Secretoglobin Family 1A Member 1	Protein Coding	11.1	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11589348 11028653 14665489 (more) 15297273 12014016 11193763 14551164 19995708 15467329
13	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	11.08	DISEASES inferred ¹⁴ ¹⁴
14	IL1B	Interleukin 1 Beta	Protein Coding	10.84	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8473683 11127488 9184656 (more) 1555841 11790645 8179912 2394137 8834333 8219777 8769489 9186988 9500293 16837501 7836771 19046553 8277611 8325116 16163465 12921647 8833992 8032714 8239179 19117745 8031681 8109465 12746045 9300729 1849808 9353154 18654018 1806183
15	IL12RB1	Interleukin 12 Receptor Subunit Beta 1	Protein Coding	10.6	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17827837 15004750 10508796
16	CCL2	C-C Motif Chemokine Ligand 2	Protein Coding	10.36	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9789895 9528906 12413001 (more) 8118632 12449175 15481270 10515417 7589391 16166739 19046553 9176534 10384061 10988120 18069417 15281432 11031344
17	CCL3	C-C Motif Chemokine Ligand 3	Protein Coding	10.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9528906 12746045 11803051 (more) 12449175 10384061
18	SERPINA3	Serpin Family A Member 3	Protein Coding	10.22	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	8777970
19	CCL18	C-C Motif Chemokine Ligand 18	Protein Coding	10.11	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19808030 12161279
20	CXCL9	C-X-C Motif Chemokine Ligand 9	Protein Coding	9.96	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16505042 17035428 15956791
21	MIF	Macrophage Migration Inhibitory Factor	Protein Coding	9.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12180727 9888451 17005573 (more) 19220835 8302732 2260882 16391884
22	ADA	Adenosine Deaminase	Protein Coding	9.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7907809 10410539 8154388 (more) 10444948 8622268 9292691 7913976
23	ICAM1	Intercellular Adhesion Molecule 1	Protein Coding	9.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1680610 10192761 1355420 (more) 10208208 8926620 7918844 7688418 7781359 7904545 19077082 7904572 1356670 11817671 9797497 7905208 10765645
24	SFTPD	Surfactant Protein D	Protein Coding	9.56	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	20151281 19995708 14665489 (more) 11936520 19046553
25	CCL5	C-C Motif Chemokine Ligand 5	Protein Coding	9.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9192918 12449175 11844139 (more) 10988120 9533940 19117745 7513016 11031344 11803051
26	IL2RB	Interleukin 2 Receptor Subunit Beta	Protein Coding	9.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1753540 9686498 18609101 (more) 2067152 9987484 2118691
27	LTA	Lymphotoxin Alpha	Protein Coding	9.19	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10547277 10488747 15713215 (more) 7482498 9349405 11243953 18062795
28	IL13	Interleukin 13	Protein Coding	9.15	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12775866 15230818 12670722 (more) 11091281
29	SLC11A1	Solute Carrier Family 11 Member 1	Protein Coding	8.99	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10837363 15702130 18496987 (more) 15004750
30	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	8.84	DISEASES inferred ¹⁴ ¹⁴
31	CXCR6	C-X-C Motif Chemokine Receptor 6	Protein Coding	8.81	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16100013 17615381 16393323
32	IL12RB2	Interleukin 12 Receptor Subunit Beta 2	Protein Coding	8.75	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15004750
33	CXCL10	C-X-C Motif Chemokine Ligand 10	Protein Coding	8.72	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16505042 11295656 16100013
34	CXCL5	C-X-C Motif Chemokine Ligand 5	Protein Coding	8.71	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17052298 19117745 17035428
35	IL1A	Interleukin 1 Alpha	Protein Coding	8.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	2266623 2243462 11790645 (more) 1555841 18654018 19117745 9749865 7586698 12737276
36	S100A9	S100 Calcium Binding Protein A9	Protein Coding	8.49	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15948122
37	IL9	Interleukin 9	Protein Coding	8.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	13678433 10629460 11123348 (more) 8648147
38	IL15	Interleukin 15	Protein Coding	8.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8752945 9719492 18654018 (more) 10705307 11742275 9764949 10444517
39	CYP27B1	Cytochrome P450 Family 27 Subfamily B Member 1	Protein Coding	8.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11403752 12233073 20082271
40	CD4	CD4 Molecule	Protein Coding	8.17	DISEASES inferred ¹⁴
41	HLA-DQB1	Major Histocompatibility Complex, Class II, DQ Beta 1	Protein Coding	8.1	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12554629
42	IFNGR2	Interferon Gamma Receptor 2	Protein Coding	8.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15004750 17937105
43	CD69	CD69 Molecule	Protein Coding	7.96	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14977779 18641108
44	CD80	CD80 Molecule	Protein Coding	7.88	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15942292 17330189 10461083
45	CD86	CD86 Molecule	Protein Coding	7.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10461083 15942292
46	CCL4	C-C Motif Chemokine Ligand 4	Protein Coding	7.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10384061 11031344 19046553
47	CHI3L1	Chitinase 3 Like 1	Protein Coding	7.83	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17236752 15763444
48	IL1RN	Interleukin 1 Receptor Antagonist	Protein Coding	7.77	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11127488 11790645 8277611 (more) 1531398 16163465 19281539
49	CD8A	CD8a Molecule	Protein Coding	7.74	DISEASES inferred ¹⁴
50	STAT1	Signal Transducer And Activator Of Transcription 1	Protein Coding	7.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19464956

Sources

Variations for Sarcoidosis 1

ClinVar genetic disease variations for Sarcoidosis 1:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	HLA-DRB1	HLA-DRB1, HLA-DRB1*1101	VAR	Risk Factor	14905		GRCh37: GRCh38:

Sources

Expression for Sarcoidosis 1

Search GEO for disease gene expression data for Sarcoidosis 1.

Sources

Pathways for Sarcoidosis 1

Pathways related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 54)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.97	TNF SERPINA3 NOD2 IL2RA IL1B IL18
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.84	TNF IL2RA IL1B IL18 IL12RB1 CXCR3
3	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.61	TNF IL2RA IL1B IL18 IL12RB1 IFNG
4	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.55	TNF IL2RA IL1B IL18 IL12RB1 IFNG
5	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.36	TNF IL2RA IL1B IL18 IL12RB1 CXCR3
6	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.32	TNF NOD2 IL2RA IL1B IL18 IL12RB1
7	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.06	TNF IL2RA IL1B IL18 IL12RB1 CXCR3
8	CCR5 Pathway in Macrophages ⁶⁴ Show member pathways Androgen Signaling ⁶⁴ Chemokine Signaling ⁶⁴ Chemokine signaling pathway ⁷⁴	12.89	CXCR3 CXCL9 CCR6 CCL3 CCL2 CCL18
9	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.84	TNF IL2RA IL1B CXCL9 CCL3
10	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.66	TNF IL2RA IL1B IL18 IL12RB1 IFNG
11	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.62	CCL2 CXCL9 IFNG IL12RB1 IL18 IL1B
12	NF-kappaB Signaling ³	12.59	TNF IL2RA IL1B IFNG CCL2
13	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.51	TNF NOD2 IL1B IL18
14	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.17	TNF IL12RB1 IFNG HLA-DRB1
15	Spinal cord injury ⁷⁴	12.03	TNF IL1B IFNG CCL2
16	Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions ⁶⁵ Show member pathways Chemokine receptors bind chemokines ⁶⁶	12.01	CXCR3 CXCL9 CCR6 CCL3 CCL2 CCL18
17	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	12	IFNG IL12RB1 IL18 IL1B TNF
18	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.99	TNF IL1B IL18 CCL2
19	CCL18 signaling pathway ⁷⁴	11.93	CCR6 CCL3 CCL2 CCL18
20	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.85	IL1B IL12RB1 IFNG
21	IL12-mediated signaling events ⁶¹ Show member pathways Immune response IL-12-induced IFN-gamma production ²²	11.84	CCL3 IFNG IL12RB1 IL18 IL1B IL2RA
22	Activation of NF-KappaB by PKR ⁶⁴ Show member pathways Canonical NF-kB pathway ⁷⁴ Cellular Transformation by HTLV1 ⁶⁴ Inhibition of PKR ⁶⁶ STING pathway in Kawasaki-like disease and COVID-19 ⁷⁴	11.79	TNF IL1B IFNG
23	Burn wound healing ⁷⁴	11.76	TNF IL1B CCL2
24	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.75	TNF IL1B IFNG
25	Lung fibrosis ⁷⁴	11.73	CCL2 CCL3 IL1B TNF
26	Th17 cell differentiation pathway ⁷⁴	11.72	IL2RA IL1B IFNG
27	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ⁶¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ⁶¹	11.7	TNF IL2RA IFNG
28	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.68	TNF NOD2 IL18 IL12RB1 IFNG
29	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.67	TNF IL1B IFNG
30	Non-genomic actions of 1,25 dihydroxyvitamin D3 ⁷⁴	11.62	TNF NOD2 IFNG CCL2
31	Allograft rejection ⁷⁴	11.6	TNF IL2RA IL1B IFNG HLA-DRB1 CXCL9
32	SARS-CoV-2 innate immunity evasion and cell-specific immune response ⁷⁴	11.58	TNF CCL3 CCL2
33	THC Differentiation Pathway ⁶⁴	11.54	TNF IL2RA IL18 IL12RB1 IFNG HLA-DRB1
34	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	11.52	TNF IL1B IFNG
35	MSP-RON Signaling ⁶⁴	11.48	TNF IL1B IL18 IFNG CCL2
36	Nucleotide-binding oligomerization domain (NOD) pathway ⁷⁴	11.47	NOD2 IL1B IL18
37	IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵ Show member pathways IL-2 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.46	TNF IL2RA IFNG CCL3
38	Interleukin-10 signaling ⁶⁶	11.44	TNF IL1B IL18 CCL3 CCL2
39	Type II interferon signaling ⁷⁴	11.42	IL1B IFNG CXCL9
40	Development and heterogeneity of the ILC family ⁷⁴	11.4	TNF IL1B IL18 IFNG
41	Cytokines and inflammatory response ⁷⁴	11.35	TNF IL1B IFNG HLA-DRB1
42	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway ⁷⁴	11.32	CCL2 IL1B TNF
43	Interactions of natural killer cells in pancreatic cancer ⁷⁴	11.31	TNF IFNG CCL3 CCL2
44	IL12 signaling mediated by STAT4 ⁶¹	11.27	IL2RA IL18 IFNG
45	IL1 and megakaryocytes in obesity ⁷⁴	11.24	IL1B IL18 IFNG CCL2
46	Immune response_IL-12 signaling pathway ²²	11.22	IL2RA IL12RB1 IFNG
47	Innate Lymphoid Cells Differentiation ⁶⁵	11.18	TNF IL2RA IL1B IL18 IL12RB1 IFNG
48	Cellular roles of Anthrax toxin ⁶¹	11.1	TNF IL1B IL18
49	Genes associated with the development of rheumatoid arthritis ⁷⁴	11.07	IL2RA HLA-DRB1 CCR6
50	G-protein signaling_Rap2B regulation pathway ²²	11.07	TNF IL1B IL18 CXCL9 CCL3 CCL2

Sources

GO Terms for Sarcoidosis 1

Cellular components related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	10.2	TNF SERPINA3 SCGB1A1 IL1B IL18 IFNG
2	extracellular space	GO:0005615	10.07	ACE CCL18 CCL2 CCL3 CHIT1 CXCL9
3	external side of plasma membrane	GO:0009897	9.58	TNF IL2RA IL12RB1 HLA-DRB1 CXCR3 CXCL9

Biological processes related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

(show all 46)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	10.48	CCL18 CCL2 CCL3 CCR6 CXCL9 CXCR3
2	cell-cell signaling	GO:0007267	10.36	CCL18 CCL3 CXCL9 IL18 IL1B
3	positive regulation of ERK1 and ERK2 cascade	GO:0070374	10.33	TNF NOD2 HLA-DRB1 CCL3 CCL2 CCL18
4	cellular response to lipopolysaccharide	GO:0071222	10.28	TNF NOD2 IL1B CXCL9 CCL2
5	chemotaxis	GO:0006935	10.27	CCL18 CCL2 CCL3 CCR6 CXCL9 CXCR3
6	positive regulation of interleukin-6 production	GO:0032755	10.26	TNF NOD2 IL1B IFNG
7	calcium-mediated signaling	GO:0019722	10.25	CCL3 CCR6 CXCR3 TNF
8	positive regulation of type II interferon production	GO:0032729	10.23	IL12RB1 IL18 IL1B TNF
9	defense response to Gram-positive bacterium	GO:0050830	10.22	IL18 IL1B NOD2 TNF
10	cellular response to type II interferon	GO:0071346	10.22	CCL18 CCL2 CCL3 IL12RB1 TNF
11	MAPK cascade	GO:0000165	10.22	TNF NOD2 IL1B IL18 CCL3 CCL2
12	positive regulation of NIK/NF-kappaB signaling	GO:1901224	10.21	IL18 IL1B NOD2 TNF
13	positive regulation of interleukin-1 beta production	GO:0032731	10.21	TNF NOD2 IFNG CCL3
14	neutrophil chemotaxis	GO:0030593	10.21	IL1B CXCL9 CCL3 CCL2 CCL18
15	response to lipopolysaccharide	GO:0032496	10.19	ACE IL1B NOD2 SCGB1A1 TNF
16	regulation of insulin secretion	GO:0050796	10.18	TNF IL1B IFNG
17	protein kinase B signaling	GO:0043491	10.18	TNF IL1B CCL3 CCL2
18	monocyte chemotaxis	GO:0002548	10.17	CCL3 CCL2 CCL18
19	positive regulation of phagocytosis	GO:0050766	10.17	TNF NOD2 IL1B IFNG
20	negative regulation of T cell proliferation	GO:0042130	10.16	HLA-DRB1 IL2RA SCGB1A1
21	negative regulation of type II interferon production	GO:0032689	10.16	SCGB1A1 NOD2 HLA-DRB1
22	positive regulation of nitric oxide biosynthetic process	GO:0045429	10.16	TNF IL1B IFNG
23	response to bacterium	GO:0009617	10.16	TNF CXCL9 CHIT1 CCL2
24	positive regulation of inflammatory response	GO:0050729	10.15	TNF IL1B IL18 IFNG CCL3 ACE
25	lymphocyte chemotaxis	GO:0048247	10.14	CCL3 CCL2 CCL18
26	positive regulation of activated T cell proliferation	GO:0042104	10.13	IL2RA IL18 IL12RB1
27	humoral immune response	GO:0006959	10.13	CCL2 CCR6 HLA-DRB1 IFNG TNF
28	cell chemotaxis	GO:0060326	10.12	CXCR3 CCR6 CCL3 CCL2
29	positive regulation of chemokine production	GO:0032722	10.1	IFNG IL18 IL1B TNF
30	positive regulation of nitric-oxide synthase biosynthetic process	GO:0051770	10.09	NOD2 IFNG CCL2
31	positive regulation of membrane protein ectodomain proteolysis	GO:0051044	10.08	TNF IL1B IFNG
32	astrocyte activation	GO:0048143	10.06	TNF IL1B IFNG
33	chemokine-mediated signaling pathway	GO:0070098	10.03	CXCR3 CXCL9 CCR6 CCL3 CCL2 CCL18
34	lipopolysaccharide-mediated signaling pathway	GO:0031663	10.02	CCL2 CCL3 IL18 IL1B TNF
35	positive regulation of neuroinflammatory response	GO:0150078	10.01	TNF IL1B IL18
36	positive regulation of NMDA glutamate receptor activity	GO:1904783	9.99	IFNG CCL2
37	positive regulation of humoral immune response mediated by circulating immunoglobulin	GO:0002925	9.99	TNF NOD2
38	positive regulation of fever generation	GO:0031622	9.98	TNF IL1B
39	sequestering of triglyceride	GO:0030730	9.97	TNF IL1B
40	positive regulation of nitrogen compound metabolic process	GO:0051173	9.96	TNF IFNG
41	inflammatory response	GO:0006954	9.96	CCL18 CCL2 CCL3 CXCL9 CXCR3 IL18
42	negative regulation of gap junction assembly	GO:1903597	9.94	IL1B ACE
43	positive regulation of vitamin D biosynthetic process	GO:0060557	9.93	TNF IFNG
44	cellular response to organic cyclic compound	GO:0071407	9.93	CCL2 CCL3 IL18 IL1B NOD2 TNF
45	positive regulation of calcidiol 1-monooxygenase activity	GO:0060559	9.88	TNF IL1B IFNG
46	immune response	GO:0006955	9.62	TNF IL2RA IL1B IL18 IFNG HLA-DRB1

Molecular functions related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	CCR chemokine receptor binding	GO:0048020	9.63	CCL3 CCL2 CCL18
2	chemokine activity	GO:0008009	9.56	CXCL9 CCL3 CCL2 CCL18
3	cytokine activity	GO:0005125	9.44	TNF IL1B IL18 IFNG CXCL9 CCL3